Ivonescimab Outperforms Standard Immunotherapy in Biliary Tract Cancer

The clinical trial, conducted as a randomized, double-blinded, multicenter study, also met all key secondary endpoints, including progression-free survival and objective response rates. By surpassing the efficacy of durvalumab, which currently serves as the preferred first-line immunotherapy, the results establish a potential new benchmark for treating this aggressive malignancy.

Dr. Michelle Xia, CEO of Akeso, characterized the findings as a major breakthrough, marking the first time the company’s ivonescimab therapy has shown positive results in gastrointestinal tumors. This success follows four successful Phase III trials in lung cancer, signaling the drug’s potential to address a broader range of solid tumors. Detailed data from the trial will be presented at an upcoming international academic conference and submitted to a peer-reviewed journal.